Poster Sessions
Poster Session VI
Anthony Traboulsee, Stephen Hauser, Eva Havrdova, Ludwig Kappos, Michael Racke, Krzysztof Selmaj, Shibeshih Belachew, Corrado Bernasconi, Donatella Morandi, Hideki Garren, Wei Wei, Douglas Arnold
P6.339 Long-term Efficacy of
Teriflunomide in Patients Recently Diagnosed With Relapsing Forms of MS —Jiwon Oh, Mark Freedman, Aaron Miller, Kathinathan Thangavelu, Philippe Truffinet, Giancarlo Comi
P6.340 Treatment with interferon
reduces the appearance of lesions in clinically relevant white matter (WM) tracts in patients with clinically isolated syndrome (CIS) —Marco Battaglini,
Hugo Vrenken, R Tappa Brocci, G Gentile, L Luchetti, A Versteeg, Mark Freedman, Bernard Uitdehaag, Ludwig Kappos, Giancarlo Comi, Frederik Barkhof, Nicola De Stefano
P6.341 Benefit of Long-term
Treatment With Teriflunomide on Disability Outcomes: Results From TEMSO and TOWER —Fred Lublin, Mark
CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion —Amy
Lovett-Racke, Yue Liu, Michael Racke, Richard Shubin, Sibyl Wray, Wendy Su, James Eubanks, Edward Fox
P6.349 Cladribine tablets in
the ORACLE-MS study open-label maintenance period: analysis of efficacy in patients after conversion to clinically definite multiple sclerosis (CDMS) —Giancarlo Comi, Thomas Leist,
Mark Freedman, Bruce Cree, Patricia Coyle, Hans-Peter Hartung, Patrick Vermersch, Doris Damian, Fernando Dangond
P6.350 In treatment-naive patients
with relapsing-remitting multiple sclerosis (RRMS), initiating natalizumab earlier is associated with greater disability improvement than delaying treatment: real-world results from the TYSABRI® Observational Program (TOP) —Timothy Spelman, Helmut
Freedman, Giancarlo Comi, Aaron Miller, Kathinathan Thangavelu, Philippe Truffinet, Ludwig Kappos
Butzkueven, Ludwig Kappos, Maria Trojano, Heinz Wiendl, Yi Chen, Nolan Campbell, Stephanie Licata, Pei-Ran Ho
P6.342 Assessment of the effect
P6.351 Defining High Disease
of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis —
Subhash Tummala, Shahamat Tauhid, Shelley Hurwitz, Rohit Bakshi
P6.343 Clinical Efficacy of
Interferon β-1a Subcutaneously Three Times Weekly According to Baseline Radiological Characteristics: Post Hoc Analyses of PRISMS Data —Flavia Nelson, Gary Cutter, Kathleen Hawker, Julie Aldridge, Anthony Reder
P6.344 The RADIANCE and
SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics —
Bruce Cree, Krzysztof Selmaj, Jeff Kopicko, Tjalf Ziemssen, Nicola De Stefano, Amit BarOr, Giancarlo Comi, Douglas Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Havrdova, Ludwig Kappos, Jeffrey Cohen
P6.345 5 years effectiveness of
fingolimod in daily clinical practice: results of the non-interventional study PANGAEA documenting RRMS patients treated with fingolimod in Germany —
Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study —Gavin Giovannoni, Kottil Rammohan, Stuart Cook, Giancarlo Comi, Peter Rieckmann, Per Soelberg-Sorensen, Patrick Vermersch, Fernando Dangond, Christine Hicking
P6.352 Efficacy of Delayed-release
Dimethyl Fumarate at Seven-Year Follow-up in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of DEFINE, CONFIRM and ENDORSE —Ralf Gold, Gavin Giovannoni, J. Theodore Phillips, Robert Fox, James Xiao, Catherine Miller
P6.353 Durable efficacy of
cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies —Per Soelberg-Sorensen, Gavin
Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Patrick Vermersch, Christine Hicking, Abidemi Adeniji, Fernando Dangond
P6.354 Interferon BETA-1B Efficacy
Tjalf Ziemssen, Holger Albrecht, Judith Haas, Luisa Klotz, Michael Lang, Chrstoph Lassek, Stephan Schmidt, Bjorn Tackenberg, Christian Cornelissen
in Real-life Clinical Setting: A Long-term Follow-up Study —Rocco Totaro, Caterina
P6.346 Effect of oral fingolimod
P6.355 Highly active relapsing
treatment on brain volume loss in patients with relapsing-remitting multiple sclerosis estimated using Bayesian methodology —Guosheng Yin, Xiangyi Meng, M. Zahur Islam
P6.347 Short and long-term
FRIDAY
predictors of relapses or disability worsening in patients with multiple sclerosis in the phase 3 TRANSFORMS study —Pavle Repovic, Aaron Boster, Xiangyi
Di Carmine, Samanta Sciamanna, Carmine Marini, Antonio Carolei
remitting multiple sclerosis following hematopoietic stem cell transplantation: a case report —Amanda Piquet, Laura Baldassari, M. Paz Soldan
P6.356 Real-life long-term
effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort —Chiara Zecca, Serge Roth,
Meng, Daniela Piani Meier, Fernanda Boulos, Till Sprenger, Frederik Barkhof
Oliver Findling, Guillaume Perriard, Valérie Bachmann, Misha Pless, Andreas Baumann, Christian Kamm, Patrice LaLive, Adam Czaplinski
P6.348 Preliminary results of Phase
P6.357 Predictors of Disability in
2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-
Relapsing-Remitting Multiple Sclerosis (RRMS) During the Glatiramer Acetate
136 2017 AAN Annual Meeting Scientific Program
Friday, April 28 8:30 a.m.—5:30 p.m. Low-frequency Administration (GALA) Study —Jessica Alexander, Donald Daudt,
Mat Davis, Natalia Ashtamker, Scott Kolodny
P6.358 Effect of early versus delayed treatment (DT) with subcutaneous IFN β-1a (scIFNβ-1a) on radiological activity free (RAF) or clinical activity free (CAF) status in patients with clinically isolated syndrome (CIS): A post-hoc analysis of REFLEXION —Mark Freedman, Giancarlo Comi, Patricia Coyle, Liang Chen, Kurt Marhardt, Ludwig Kappos
P6.359 Multi-center, randomized,
double-blinded assessment of teriflunomide in extending the time to a first clinical event in radiologically isolated syndrome (RIS) The TERIS study —Christine Lebrun Frenay, Aksel Siva, Orhun Kantarci, Christina Azevedo, Maria Pia Sormani, Daniel Pelletier, Darin Okuda
P6.360 Efficacy of Cladribine Tablets
3.5 mg/kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study —Gavin Giovannoni, Kottil Rammohan,
Stuart Cook, Giancarlo Comi, Peter Rieckmann, Per Soelberg-Sorensen, Patrick Vermersch, Fernando Dangond, Christine Hicking
P6.361 Impact of Long-term
Teriflunomide Treatment on Severe Relapses: Analysis of TEMSO and TOWER Extensions —Mathias Maurer,
Aaron Miller, Giancarlo Comi, Ludwig Kappos, Jerry Wolinsky, Martin Stangel, Richard Macdonell, Philippe Truffinet, Kathinathan Thangavelu, Mark Freedman
P6.362 Teriflunomide Is Effective in
Reducing Brain Volume Loss in Previously Treated Patients: A Subgroup Analysis of TEMSO SIENA Data —Mark Freedman, Till Sprenger, Ernst-Wilhelm Radue, Jens Wuerfel, Aaron Miller, Kathinathan Thangavelu, Steven Cavalier,
P6.363 Effectiveness of Delayed-
release Dimethyl Fumarate on Clinical Measures and Patient-reported Outcomes in Newly Diagnosed and Other Early Relapsing-Remitting Multiple Sclerosis Patients: Subgroup Analysis of PROTEC —Thomas Berger, Bruno Brochet, Paolo Confalonieri, Paul Giacomini, Xavier Montalban, Antonio Salgado, Macaulay Okwuokenye, Monica Fay, Adrien Bretagne
P6.364 Prolonged-Release
Fampridine Induces Sustained Clinically Meaningful Improvements in Walking Ability in People with Multiple Sclerosis: Results from the ENHANCE Trial —
Jeremy Hobart, Tjalf Ziemssen, Peter Feys, Michael Linnebank, Andrew Goodman, Rachel Farrell, Veronica Englishby, Manjit McNeill, Ih Chang, Lahar Mehta, Jacob Elkins
P6.365 Effectiveness of fingolimod
in patients with relapsing-remitting multiple sclerosis in daily clinical practice in Spain: results from the multivariate pooled analysis Fingoview. —Jose Meca Lallana, Guillermo Izquierdo, Jose Ramon Ara, Celia Oreja-Guevara, Lucia Forero Diaz, Lucia, Teresa Ayuso, Angel Sempere, Nicholas Herrera, Yessica Contreras, Irene SanchezVera, Maria Jose Moreno Jimenez, Francisco Javier Ricart, Eli Garcia
COMPARATIVE EFFICACY OF DISEASE MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS
P6.366 Comparison of Adherence
and Persistence to Glatiramer Acetate 40 mg/mL Three-Times Weekly Subcutaneous Injections Versus Oral Therapies in Multiple Sclerosis —Helen
Trenz, Djibril Liassou, Ryan Wolbeck, Ravi Iyer, Ying Wu
P6.367 SC peginterferon beta-1a
every 2 weeks demonstrated better clinical outcomes than SC interferon beta-1a TIW in patients with RMS, using a matching-adjusted comparison of 5 Phase 3 trials —Patricia Coyle, Shulian Shang, Carmen Castrillo-Viguera
P6.368 Peginterferon Beta-1a
Demonstrated Better Clinical Outcomes than Teriflunomide in Patients with Relapsing MS, Using a Matchingadjusted Comparison of Phase 3 Trials —
Scott Newsome, Maria Naylor, Shulian Shang, Carmen Castrillo-Viguera
P6.369 Comparison of treatment
retention and efficacy outcomes with fingolimod, interferons and glatiramer acetate in PREFERMS —Florian Thomas,
Douglas Arnold, Mark Cascione, Edward Fox, Cecilia Vieira Da Silva, John Ko, Xiangyi Meng, Lesley Schofield, Fernanda Boulos, Nadia Tenenbaum, Bruce Cree
P6.370 A Bayesian Random Effects Mixed Treatment Comparison of Daclizumab Versus Other Disease Modifying Treatments for RelapsingRemitting Multiple Sclerosis —Craig Wakeford, Richard Birnie, Robert Wolff, Elizabeth Kinter, Guido Sabatella, Giorgio Giannattasio, Xiaolan Ye, Ying Liu, Jos Kleijnen
P6.371 Advanced Myelin-related
MRI Measures in Relapsing Multiple Sclerosis Patients treated with Ocrelizumab or Interferon Beta-1a Over 96 Weeks —Shannon Kolind, Irene Vavasour, Lisa Tang, Roger Tam, Alexander Rauscher, David Clayton, Victoria Levesque, Robert Carruthers, Rick White, David Li, Anthony Traboulsee
P6.372 Comparative analysis of MS
outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide —Timothy
Spelman, Tomas Kalincik, Maria Trojana, Francois Grand-Maison, Guillermo Izquierdo, Eva Havrdova, Dana Horakova, Alessandra Lugaresi, Pierre Duquette, Pierre Grammond, Raymond Hupperts, Jeannette Lechner-Scott, Franco Granella, Thor Peterson, Murat Terzi, Eugenio Pucci, Patrizia Sola, Vincent Van Pesch, Gerardo Iuliano, Cavit Boz, Roberto Bergamaschi, Mark Slee, Helmut Butzkueven
P6.373 Comparable efficacy of
fingolimod and natalizumab in real life study —Roberta Lanzillo, Antonio Carotenuto, Marcello Moccia, Cinzia Valeria Russo, Chiara Criscuolo, Luigi Lavorgna, Marco Massarelli, Anna De Rosa, Francesco Sacca, Vincenzo Brescia Morra
P6.374 A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a